Lyndra Therapeutics is pioneering long-acting oral therapies through its proprietary LYNX™ drug delivery platform, with the potential to revolutionize oral drug delivery by providing week-long or longer dosing in an oral form. The company's core purpose is to reinvent medicine for a healthier world, and it has achieved rapid progress in formulating therapies and advancing products to the clinic.

Welcome to Lyndra Therapeutics: Medicine, reinvented
 
Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible.
 
Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication.
 
Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.
 
Core purpose: reinvent medicine for a healthier world
 
Core values: value every voice; resilient to the core; I contribute, we deliver
 
Does Lyndra sound like a great fit for you? Join the Team: https://lyndra.com/about/join-the-team/

AIG Investments

Polaris Partners

Quark Venture

Limitless Ventures

Mass General Brigham Ventures

THE CATALYTIC IMPACT FOUNDATION (CIF)

Yipinhong Pharmacy

Gilead Sciences

HOPU Investment Management Company

ImpactAssets

Sarissa Capital Management

Sun Pharmaceutical Industries

Lyndra Therapeutics

At Lyndra, our team is eager to bring long-acting oral therapies to people who need them. Today, we announced positive data from our pivotal phase 3 study of oral weekly risperidone (LYN-005) for schizophrenia. As our Chief Medical Officer and President of Global Product Development, Richard Scranton MD MPH shared, “These positive data demonstrate that a single dose of oral weekly risperidone delivers comparable medication levels to daily risperidone, validating that Lyndra’s LYNX® drug delivery platform may provide a medication option that significantly reduces dosing frequency. For people who rely on risperidone as part of their treatment regimen, oral weekly risperidone could vastly improve medication adherence and outcomes.”

This is a major step forward towards our goal of bringing long-acting oral medicines based on the LYNX drug delivery platform to the people who need them most and transforming how we take medicines. 

At Lyndra, we are passionate about building a healthier world through long-acting oral therapies. Today, we announced the close of a $101 Million Series E funding round to support that mission, led by Sarissa Capital Management LP and including SUN PHARMA and Polaris Partners These funds will support the development of therapies with our LYNX® drug delivery platform, including oral weekly risperidone (LYN-005), which is nearing completion of phase 3 clinical study.

“We appreciate the support our investors are providing as we complete our risperidone phase 3 trials and continue the development of our pipeline of oral weekly therapies through this round of financing,” said Jessica Ballinger, Lyndra President and CEO. “This investment validates the LYNX platform and moves us forward in our plans to bring our lead product candidate, oral weekly risperidone, through the regulatory pathway and to patients.”


We’re honored to share that our President & CEO, Jessica Ballinger , has been recognized in this year’s PharmaVoice Top 100. Congratulations, Jess! 

To learn more visit: https://lnkd.in/gwb4f7Rz
#leadership #pharmavoice100 #trailblazer 

August 31st marks International Overdose Awareness Day. As such, we honor those who have lost their lives to the drug overdose epidemic and acknowledge the grief of family and friends left behind. As a company working to create long-acting oral medications for people living with opioid use disorder with support from The National Institutes of Health’s The National Institute on Drug Abuse (NIDA), we want to take the time to remember the lives lost to the drug overdose epidemic. We look towards a future where people living with addiction have access to the help they need. #NIH #NIDA

COM:LYNDRA

Lyndra Therapeutics

Analysis Not Available